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Cystic ﬁbrosis (CF) can be diagnosed in several ways. In utero, several clues may
suggest it, the most common being the presence of a foetal echogenic bowel (FEB)
detected at ultrasound during pregnancy. Other elements, as nonvisualized foetal
gallbladder (NFG) are also possible evidences for CF.
Based on the experience of 4 university hospitals (Brest, Rennes, Nantes, Poitiers)
of western France, this study reports the data of NFG, focused on CF, and assesses
the absence of gallbladder as a component in achieving a CF diagnosis.
We reviewed all the consecutive cases of NFG in pregnant women and who were
referred for an analysis of the gene responsible for CF (CFTR) over the period
2002–2009.
Over that period, 38 NFG were recorded. We identiﬁed 5 CF foetuses
(F508del/F508del n = 2, F508del/937insT n = 1, F508del/4005+1G>A n= 1,
F508del/R553X n= 1) and 3 heterozygous ones. This led respectively to a CF
prevalence of 13.2% (1/7.5) and a carrier rate of 7.9% (1/12.6) in NFG foetuses.
The ﬁrst rate was signiﬁcantly higher than in the global population (1/2 928). For all
CF foetuses, NFG was associated with FEB, whereas heterozygous patients showed
only NFG. All affected pregnancies were terminated.
We highlighted the importance of viewing or not the gallbladder during pregnancy.
In our study, NFG seems to be an essential element to consider in achieving a
diagnosis of CF, especially when associated with FEB (all the CF foetuses have
both).
Support: Programme Hospitalier de Recherche Clinique.
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Fetal bowel hyperechogenicity and loop dilatation that are observed at the second
trimester of pregnancy can be due to several disease conditions, including CF.
Screening for frequent CF mutations is performed in a ﬁrst row and is followed, in
particular cases, by an in-depth study. We collated data on 694 referrals related
to suspicion of CF in fetuses from 1992 to 2009, in an attempt to provide
comprehensive description of CFTR genotypes, correlations with ultrasound signs
and risk reappraisal. A group of 465 ﬁrst-hand referrals was distinguished from
another of 229 second-hand referrals that had a ﬁrst study in another laboratory.
In the 1st group, CF was found in 2.1% of fetuses, CFTR-RD in 0.6% and simple
heterozygosity in 3%. The residual risk of CF in fetuses carrying one frequent
mutation, evaluated from data of the 2 groups, was assessed at 20%. In total,
5 large deletions were identiﬁed, of which 3 were new, accounting for 10.3% of CF
alleles.
Correlation with ultrasound signs revealed a signiﬁcant higher frequency of multiple
digestive signs in CF (55%), such as hyperechogenic bowel, loop dilatation and
non-visualization of gallbladder, than in non-CF fetuses (20%).
In conclusion, this study shows heterogeneity of CFTR genotypes associated with
varied combinations of bowel anomalies, leading to a CF or CFTR-RD diagnosis,
as is observed for CF newborn screening. It also strongly strengthens the need to
consider large CFTR gene rearrangements in the diagnosis strategy.
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From 1988 we have recruited 1,000 CF patients/families for genetic testing. In our
current strategy, CFTR gene study is carried out in successive steps: 1) commercial
kit for the detection of common mutations; 2) microsatellite analysis (IVS8CA,
IVS17bTA) to determine those haplotypes associated to another common mutation
or large rearrangement already identiﬁed in the Spanish patients and/or to detect loss
of heterozygosity; 3) CFTR gene scanning for samples yet uncharacterized using
single strand conformation polymorphism (SSCP/HD) and denaturing gradient gel
electrophoresis (DGGE) techniques followed by sequencing of abnormal patterns;
4) MLPA analysis to detect rearrangements in samples with yet CF unknown alleles.
Any abnormal MLPA proﬁle is conﬁrmed by direct analysis or quantitative real-
time PCR. When necessary, other complementary studies are performed: in silico
analysis, array-CGH to characterize novel rearrangements and/or RNA analysis.
Moreover, segregation study is carried out to conﬁrm the CF genotype. Genetic
counselling, carrier detection and prenatal diagnosis are offered to the families.
Overall, we have identiﬁed above 200 mutations with a detection rate of 97%.
The F508del accounts for 51% of CF alleles and other 11 point mutations show
frequencies 1%. Eight large rearrangements account for 1.3%. Our results conﬁrm
the high molecular heterogeneity of CFTR gene in the Spanish population just as
it has been described in countries of the Mediterranean area.
Supported by: ISCiii FIS PI080041 and Fundacio´n Sira Carrasco (Spain).
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Introduction: The CFTR gene has been cloned now 20 years ago, however we still
experience difﬁculties in diagnostic cases with atypical presentation and complex
mutations like R117H. This mutation is relevant in our clinic since a large proportion
of persons with positive NBS test by IRT carry a R117H mutation. In our ﬁrst period
of neonatal screening using IRT, PAP and DNA analysis we found R117H in 7 out
of 18 CF patients (40%), compared to around 1−5% in CF patients diagnosed on
clinical grounds.
Results: We diagnosed one male (age 35) and one female (age 33) carrying two
R117H (7T) mutations. The male patient presented with infertility because of
CBAVD. The female was only recognised because she underwent CFTR mutation
analysis after her son was identiﬁed with F508del/R117H by the NBS. She had no
clinical symptoms. Further characterisation showed borderline sweat tests (Cl− 34
and 42 respectively), normal sodium and chloride transport in respiratory epithelium
and pancreatic sufﬁciency.
Conclusions: These two homozygous R117H patients emphasize the complex
genotype-phenotype relationship. Our male patient only presented with CBAVD
and a borderline sweat test. In addition, in both cases NPD was normal. To
our knowledge this is a ﬁrst report on an adult female R117H-7T homozygous
individual, she was without any CF symptoms and only had a borderline sweat test.
Therefore, we suggest that R117H is associated with vas deference dysfunction in
males, but not with any CF symptoms, as was seen in compound heterozygous
patients with R117H-7T (Peckham et al 2006). We will further investigate the
genotype-phenotype relationship in R117H patients identiﬁed by the NBS tests.
